Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy

Tumor lysis syndrome (TLS) is characterized by hyperuricaemia, hyperphosphatemia, hyperkalaemia, as well as hypocalcaemia due to the breakdown of tumor cells undergoing cancer therapy (chemo/radio). Therefore it is of interest to evaluate oxidative stress using selective biological markers [Malondia...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasool, Mahmood, Malik, Arif, Qureshi, Muhammad Saeed, Ahmad, Riaz, Manan, Abdul, Asif, Muhammad, Naseer, Muhammad Imran, Pushparaj, Peter Natesan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2014
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261116/
https://www.ncbi.nlm.nih.gov/pubmed/25512688
http://dx.doi.org/10.6026/97320630010703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261116/
https://www.ncbi.nlm.nih.gov/pubmed/25512688
http://dx.doi.org/10.6026/97320630010703

Ejemplares similares